Statsenko M E, Derevianchenko M V, Pastukhova O R
Kardiologiia. 2014;54(11):20-4.
To assess effect of combined antihypertensive therapy with lisinopril and amlodipine on circadian blood pressure (BP), insulin resistance (IR), carbohydrate and lipid metabolism in patients with arterial hypertension (AH) and type 2 diabetes mellitus (DM).
Combination of amlodipine (6.0±0.4 mg/day) and lisinopril (12.0±0.9 mg/day) was given to 30 patients (age 40-65 years) with stage I-II AH and DM type 2) for 24 weeks. All patients underwent ambulatory BP monitoring. Parameter studied comprised glucose levels, glycosylated hemoglobin (HbAlc), basal insulin, lipid profile in the venous blood and insulin resistance (IR). All patients received glucose-lowering drugs and followed diet recommendations.
All patients achieved target BP values and concentrations of HbAlc. After 24 weeks of treatment the following parameters were significantly different from baseline values: mean systolic BP (SBP) (-15.6%), mean diastolic BP (DBP), (-16.2%), time index (pressure load--PL) SBP day (-50.1%), PL DBP day (-51.3), PL DBP night (-59.2%), SBP variability (-15.8%), values of morning SBP and DBP increase (both -41.8%), rates of morning rise of SBP (-74.1%) and DBP (-65.8%), percentage of patients with increased variability of SBP (-36.7%), of DBP (- 23.3%), of SBP day (-36.7%), of DBP day (-30.0%). Significant decreases of fasting blood glucose level (-22.1%), concentrations of total cholesterol (-8.8%), low density lipoprotein cholesterol (-15%), triglycerides (-4.4%), and metabolic index (-32.7%) were also observed.
In patients with hypertension and type 2 DM 24 week antihypertensive therapy with lisinopril and amlodipine significantly improved circadian blood pressure profile, reduced severity of IR without negative effect on carbohydrate and lipid metabolism.
评估赖诺普利与氨氯地平联合抗高血压治疗对动脉高血压(AH)合并2型糖尿病(DM)患者的昼夜血压(BP)、胰岛素抵抗(IR)、碳水化合物及脂质代谢的影响。
给予30例年龄在40 - 65岁、患有I - II期AH及2型DM的患者氨氯地平(6.0±0.4毫克/天)与赖诺普利(12.0±0.9毫克/天)联合治疗24周。所有患者均接受动态血压监测。研究参数包括血糖水平、糖化血红蛋白(HbAlc)、基础胰岛素、静脉血脂质谱及胰岛素抵抗(IR)。所有患者均接受降糖药物治疗并遵循饮食建议。
所有患者均达到目标血压值及HbAlc浓度。治疗24周后,以下参数与基线值相比有显著差异:平均收缩压(SBP)(-15.6%)、平均舒张压(DBP)(-16.2%)、时间指数(压力负荷 - - PL)SBP日(-50.1%)、PL DBP日(-51.3)、PL DBP夜间(-59.2%)、SBP变异性(-15.8%)、晨起SBP及DBP升高值(均为 - 41.8%)、SBP晨起上升速率(-74.1%)及DBP晨起上升速率(-65.8%)、SBP变异性增加的患者百分比(-36.7%)、DBP变异性增加的患者百分比(-23.3%)、SBP日变异性增加的患者百分比(-36.7%)、DBP日变异性增加的患者百分比(-30.0%)。还观察到空腹血糖水平显著降低(-22.1%)、总胆固醇浓度(-8.8%)、低密度脂蛋白胆固醇(-15%)、甘油三酯(-4.4%)及代谢指数(-32.7%)。
对于高血压合并2型糖尿病患者,赖诺普利与氨氯地平进行24周抗高血压治疗可显著改善昼夜血压情况,降低IR严重程度,且对碳水化合物及脂质代谢无负面影响。